Immuneering Corporation announced on December 19, 2024, the formation of its Pancreatic Cancer Advisory Board. This board comprises world-renowned oncology clinical researchers who will provide strategic medical and clinical guidance to the company.
The establishment of this advisory board reflects the clinical progress of IMM-1-104 and its potential in pancreatic cancer. This strategic move follows the recent FDA Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104.
The expertise of the board members is expected to be invaluable as Immuneering continues to advance IMM-1-104 further into clinical development. This initiative underscores the company's commitment to developing improved treatment options for pancreatic cancer patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.